Method of treating the syndrome of coronary heart disease risk factors in humans
First Claim
Patent Images
1. A method of treating a human suffering from one or more conditions included within Coronary Heart Disease Risk Factor (CHDRF) syndrome, the method comprising administering, by a pharmaceutically effective mode, a drug composition comprising:
- an opioidergic agent; and
an insulin secretagogue.
3 Assignments
0 Petitions
Accused Products
Abstract
The invention provides an improved method of treating a human suffering from one or more conditions included within the Coronary Heart Disease Risk Factor (CHDRF) syndrome. The method includes administering, by a pharmaceutically effective mode, a drug composition having an opioidergic agent including an opiate antagonist, opiate having μ-agonist activity or combination thereof, and an insulin secretagogue.
75 Citations
55 Claims
-
1. A method of treating a human suffering from one or more conditions included within Coronary Heart Disease Risk Factor (CHDRF) syndrome, the method comprising administering, by a pharmaceutically effective mode, a drug composition comprising:
-
an opioidergic agent; and
an insulin secretagogue. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)
i) dihydromorphine;
ii) morphine;
iii) hydromorphone;
iv) methadone;
v) fentanyl;
vi) sufentanyl;
vii) buprenorphine;
viii) demorphine;
ix) codeine;
x) ethylmorphine;
xi) etonitazene;
xii) hydrocodone;
xiii) levorphanol;
xiv) norcodeine;
xv) normophine;
xvi) (D-Ala2-N-Me-Phe4-Gly3-ol)-Enkephalin (DAMGO);
xvii) oxycodone; and
xviii) tramadol.
-
-
13. The method of claim 2, wherein the opioidergic agent includes at least one of the following:
-
i) nalmefene;
ii) naltrexone;
iii) nor-binaltorphimine;
iv) (−
)-(1R,5R,9R)-5,9-diethyl-2-(3-furylmethyl)-2-hydroxy-6,7-benzomorphan (MR
2266);
v) a triethylenedioxy derivative of B-naltrexamine (TENA); and
vi) guanidylated naltrindole (GNTI).
-
-
14. The method of claim 2, wherein the condition included within the CHDRF Syndrome is Insulin Resistance (IR).
-
15. The method of claim 2, wherein the condition included within the CHDRF Syndrome is Beta-Cell Dysfunction.
-
16. The method of claim 2, wherein the condition included within the CHDRF Syndrome is Impaired Glucose Tolerance (IGT).
-
17. The method of claim 2, wherein the condition included within the CHDRF Syndrome is Type 2 Diabetes.
-
18. The method of claim 2, wherein the condition included within the CHDRF syndrome is overweight.
-
19. The method of claim 2, wherein the condition included within the CHDRF syndrome is obesity.
-
20. The method of claim 2, wherein the condition included within the CHDRF syndrome is dyslipidemia.
-
21. The method of claim 1, wherein the insulin secretagogue includes at least one of the following:
-
i. sulphonylureas;
ii. tolbutamide;
iii. chlorpropamide;
iv. glimepiride;
v. glipizide;
vi. glyburide;
vii. meglitinides;
viii. repaglinide;
ix. pramlintide;
x. morphilinoguanide;
xi. acetylcholine;
xii. muscarinic agonists;
xiii. carbachol;
xiv. bethanechol;
xv. beta-L-glucose pentaacetate;
xvi. chiro-inositol;
xvii. myo-inositol;
xviii. GIP;
xix. GLP-1; and
xx. Extendin-4.
-
-
22. The method of claim 1, wherein the insulin secretagogue is a non-glucose dependent insulin secretagogue, the method producing insulin release patterns capable of attaining glucose dependent, bi-phasic release characteristics with reduced likelihood of producing hypoglycemia.
-
23. The method of claim 22, wherein the insulin secretagogue is sulphonylurea.
-
24. A method of treating a human suffering from one or more conditions included within Coronary Heart Disease Risk Factor (CHDRF) syndrome, the method comprising administering, by a pharmaceutically effective mode, a drug composition comprising:
-
an opiate antagonist; and
an insulin secretagogue. - View Dependent Claims (25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)
i) nalmefene ii) naltrexone;
iii) nor-binaltorphimine;
iv) (−
)-(1R,5R,9R)-5,9-diethyl-2-(3-furylmethyl)-2-hydroxy-6,7-benzomorphan (MR
2266);
v) a triethylenedioxy derivative of B-naltrexarnine (TENA); and
vi) guanidylated naltrindole (GNTI).
-
-
28. The method of claim 24, wherein the condition included within the CHDRF Syndrome is Insulin Resistance.
-
29. The method of claim 24, wherein the condition included within the CHDRF Syndrome is Beta-Cell Dysfunction.
-
30. The method of claim 24, wherein the condition included within the CHDRF syndrome is Impaired Glucose Tolerance (IGT).
-
31. The method of claim 24, wherein the condition included within the CHDRF syndrome is Type 2 Diabetes.
-
32. The method of claim 24, wherein the condition included within the CHDRF syndrome is overweight.
-
33. The method of claim 24, wherein the condition included within the CHDRF syndrome is obesity.
-
34. The method of claim 24, wherein the condition included within the CHDRF syndrome is dyslipidemia.
-
35. The method of claim 24 wherein the opiate antagonist has IC50 levels for the μ
- , δ
, and κ
opiate receptors, the IC50 levels being {(IC50κ
/IC50μ
)<
3} and {(IC50κ
/IC50δ
)<
3}.
- , δ
-
36. The method of claim 24, wherein the insulin secretagogue includes at least one of the following:
-
i. sulphonylureas;
ii. tolbutamide;
iii. chlorpropamide;
iv. glimepiride;
v. glipizide;
vi. glyburide;
vii. meglitinides;
viii. repaglinide;
ix. pramlintide;
x. morphilinoguanide;
xi. acetylcholine;
xii. muscarinic agonists;
xiii. carbachol;
xiv. bethanechol;
xv. beta-L-glucose pentaacetate;
xvi. chiro-inositol;
xvii. myo-inositol;
xviii. GIP;
xix. GLP-1; and
xx. Extendin-4.
-
-
37. The method of claims 24, wherein the insulin secretagogue is a non-glucose dependent insulin secretagogue, the method producing insulin release patterns capable of attaining glucose dependent, bi-phasic release characteristics with reduced likelihood of producing hypoglycemia.
-
38. The method of claim 37, wherein the insulin secretagogue is sulphonylurea.
-
39. A method of treating a human suffering from one or more conditions included within the Coronary Heart Disease Risk Factor (CHDRF) syndrome, the method comprising administering, by a pharmaceutically effective mode, a drug composition comprising:
-
an opiate agonist; and
an insulin secretagogue. - View Dependent Claims (40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)
i) dihydromorphine;
ii) morphine;
iii) hydromorphone;
iv) methadone;
v) fentanyl;
vi) sufentanyl;
vii) demorphine;
viii) codeine;
ix) ethylmorphine;
x) etonitazene;
xi) hydrocodone;
xii) levorphanol;
xiii) norcodeine;
xiv) normophine;
xv) (D-Ala2-N-Me-Phe4-Gly3-ol)-Enkephalin (DAMGO);
xvi) oxycodone; and
xvii) tramadol.
-
-
46. The method of claim 39, wherein the condition included within the CHDRF Syndrome is Insulin Resistance.
-
47. The method of claim 39, wherein the condition included within the CHDRF Syndrome is Beta-Cell Dysfunction.
-
48. The method of claim 39, wherein the condition included within the CHDRF syndrome is Impaired Glucose Tolerance (IGT).
-
49. The method of claim 39, wherein the condition included within the CHDRF syndrome is Type 2 Diabetes.
-
50. The method of claim 39, wherein the condition included within the CHDRF syndrome is overweight.
-
51. The method of claim 39, wherein the condition included within the CHDRF syndrome is obesity.
-
52. The method of claim 39, wherein the condition included within the CHDRF syndrome is dyslipidemia.
-
53. The method of claim 39, wherein the insulin secretagogue includes at least one of the following:
-
i. sulphonylureas;
ii. tolbutamide;
iii. chlorpropamide;
iv. glimepiride;
v. glipizide;
vi. glyburide;
vii. meglitinides;
viii. repaglinide;
ix. pramlintide;
x. morphilinoguanide;
xi. acetylcholine;
xii. muscarinic agonists;
xiii. carbachol;
xiv. bethanechol;
xv. beta-L-glucose pentaacetate;
xvi. chiro-inositol;
xvii. myo-inositol;
xviii. GIP;
xix. GLP-1; and
xx. Extendin-4.
-
-
54. The method of claims 39, wherein the insulin secretagogue is a non-glucose dependent insulin secretagogue, the method producing insulin release patterns capable of attaining glucose dependent, bi-phasic release characteristics with reduced likelihood of producing hypoglycemia.
-
55. The method of claim 39, wherein the insulin secretagogue is sulphonylurea.
Specification